FDA Cleared PharmaMar STARFISH-54 Platform Trial
The FDA approved a new platform trial designed to evaluate PharmaMar’s PM54 therapy for solid tumors.
Updated on Sept. 23, 2026 in Cancer

Live Poll
Do you support prioritizing faster clinical trial processes over traditional, slower evaluation methods?
The FDA has granted clearance for the STARFISH-54 platform trial to assess the effectiveness of the therapeutic agent PM54. This trial framework allows for the simultaneous evaluation of multiple drug combinations to treat solid tumors.
Why it matters
The platform trial design is intended to accelerate the pace of clinical development by creating a more efficient method for testing new therapeutic combinations. This approach aims to streamline the evaluation process to bring potential treatment options to patients faster.
The STARFISH-54 platform trial is authorized to evaluate PM54 in combination with irinotecan and doxorubicin as its first two study cohorts. The design permits the integration of new treatment cohorts as additional scientific evidence becomes available.
The players
PharmaMar
PharmaMar is a pharmaceutical company that specializes in the discovery and development of oncology treatments.
FDA
The FDA is the United States federal agency responsible for protecting public health by regulating the safety and efficacy of medical products.
The details
The trial utilizes a common protocol to simultaneously assess PM54 alongside various standard therapies for solid tumors. By establishing a flexible framework, the trial can add new arms as research progresses, facilitating a more rapid development cycle than conventional sequential testing.
Timeline
September 23, 2026: PharmaMar announced FDA clearance of the STARFISH-54 trial.
The Big Picture
This initiative follows a pattern established by other adaptive platform trials in oncology designed to test multiple therapeutic combinations efficiently. It reflects a shift toward using flexible research frameworks to accelerate the evaluation of complex cancer treatments.
The authorization of this platform trial may eventually provide patients with access to new, optimized therapeutic combinations for solid tumors. By accelerating the testing phase, the framework seeks to reduce the time required to determine the effectiveness of new treatment options.
The takeaway
Platform trials are increasingly vital for the rapid assessment of drug combinations in oncology. Patients and providers should monitor the trial progress for potential updates on future treatment availability for solid tumors.
Further reading
Learn more about advancements in Cancer research and clinical trial methodologies.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you support prioritizing faster clinical trial processes over traditional, slower evaluation methods?






